Finerenone (Kerendia)
نویسندگان
چکیده

 CADTH recommends that Kerendia be reimbursed by public drug plans as an adjunct to standard-of-care therapy in adult patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) reduce the risk of end-stage (ESKD) a sustained decrease estimated glomerular filtration rate (eGFR), cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, if certain conditions are met.
 should only covered treat CKD T2D, eGFR levels at least 25 mL/min/1.73 m2, have too much albumin their urine. not failure or who being treated mineralocorticoid receptor antagonist (e.g., spironolactone).
 prescribed consultation nephrologist experience diagnosing managing T2D cost is reduced.
منابع مشابه
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
BACKGROUND The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease. However, its effects on vascular function remain elusive. PURPOSE The aim of this study was to determine the functional effect of selective MR antagonism by finerenone in vascular cells in ...
متن کاملEffect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
IMPORTANCE Steroidal mineralocorticoid receptor antagonists, when added to a renin-angiotensin system blocker, further reduce proteinuria in patients with chronic kidney disease but may be underused because of a high risk of adverse events. OBJECTIVE To evaluate the safety and efficacy of different oral doses of the nonsteroidal mineralocorticoid receptor antagonist finerenone, given for 90 d...
متن کاملNonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
Acute kidney injury induced by ischemia/reperfusion (IR) is a frequent complication in hospitalized patients. Mineralocorticoid receptor antagonism has shown to be helpful against renal IR consequences; however, the potential benefit of novel nonsteroidal mineralocorticoid receptor antagonists such as finerenone has to be further explored. In this study, we evaluated the efficacy of finerenone ...
متن کاملFinerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Aldosterone regulates sodium homeostasis by activating the mineralocorticoid receptor (MR), a member of the nuclear receptor superfamily. Hyperaldosteronism leads todeleterious effects on the kidney, blood vessels, and heart. Although steroidal antagonists such as spironolactone and eplerenone are clinically useful for the treatment of cardiovascular diseases, they are associated with several s...
متن کاملA randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
AIMS To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus. METHODS AND RESULTS Miner Alocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF) was a randomized, double-blind, phase 2b multicentre ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2023
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2023.609